The opening week of 2026 served up a reminder that markets can pivot quickly when policy meets geopolitics. The S&P 500 and Dow Jones Industrial Average both climbed to fresh records, but the real story was happening beneath the surface. Investors were rotating out of the mega-cap tech darlings that dominated 2025 and piling into cyclical plays—particularly energy and defense—as a dramatic U.S. military operation in Venezuela and promises of surging crude supply reshaped the narrative.
Energy and defense stocks led the charge, reflecting a significant shift in market leadership. Oil-related equities rallied on optimism that Venezuela could supply sanctioned crude to U.S. markets, while defense contractors surged amid plans for a substantially larger Pentagon budget in 2027. Smaller defense contractors significantly outpaced the broader market, attracting both institutional and retail interest.
The December jobs report added a nuanced backdrop to the week's action. Payroll growth came in slower than expected, but the unemployment rate ticked down, easing concerns about labor market stress. The mixed data supported the view that the Federal Reserve might hold rates steady in the near term, keeping hopes alive for potential rate cuts later in the year.
Here's a closer look at some of the week's most notable market movers—the stocks that surged on policy tailwinds and those that tumbled when Washington changed the rules.
The Winners
Energy Stocks Ride the Venezuela Wave
Chevron Corp. (CVX) shares jumped roughly 5.8% early in the week as energy stocks rallied following U.S. actions in Venezuela. The military strike and capture of President Nicolás Maduro sent investors scrambling into oil names on optimism about potential access to the country's vast oil resources.
What made the move particularly interesting wasn't just the geopolitical catalyst—it was the Congressional trading angle. Trading records show several members of Congress holding or adding Chevron positions in 2025, including Reps. Marjorie Taylor Greene (R-Ga.) and Gilbert Cisneros (D-Calif.) and Sen. Markwayne Mullin (R-Okla.). While some lawmakers voiced concern over the U.S. intervention and others supported it, market watchers noted that tracking Congressional trading activity in oil names could remain relevant as geopolitical developments continue to shape energy stocks.
Palantir Benefits from Government Contract Speculation
Palantir Technologies Inc. (PLTR) stock showed an upward bias to start 2026, gaining momentum amid heightened interest tied to the recent U.S. military action in Venezuela and the company's deep government ties. There's no official confirmation of Palantir's involvement in the Venezuela operations, but speculation alone was enough to boost social media attention and trading interest.
The Congressional connection emerged here too. Several members of U.S. Congress held or traded Palantir shares in 2025, including Reps. Rob Bresnahan (R-Penn.), Gilbert Cisneros (D-Calif.), James Comer (R-Tenn.) and Cleo Fields (D-La.). The overlap between political exposure and government contracts created an interesting dynamic as the stock climbed on geopolitical speculation.
Nuclear Energy Gets a Federal Boost
Nuclear energy names rallied after the Trump administration unveiled expanded federal support for domestic nuclear fuel and power infrastructure. Centrus Energy Corp. (LEU), Energy Fuels Inc. (UUUU) and Ur-Energy Inc. (URG) all surged on the news.
The policy announcement included incentives for uranium mining and enrichment, streamlined permitting for nuclear projects, and increased strategic reserves. Investors saw it as a catalyst for sector growth, with traders noting broad interest from both retail and institutional buyers. Analysts cited improved earnings prospects and policy visibility as drivers behind the rally, particularly for companies positioned to benefit from long-term demand for low-carbon energy sources.
The Losers
Real Estate Stocks Crater on Trump's Housing Push
Real estate and housing-linked stocks sold off sharply after President Donald Trump announced plans to curb large institutional investors from buying single-family homes. The policy was framed as part of a broader effort to make homeownership more accessible and push back against corporate landlords.
Shares of major players including Blackstone Inc. (BX), Invitation Homes Inc. (INVH) and Opendoor Technologies Inc. (OPEN) fell as markets reacted to the policy shift. Homebuilders weren't spared either—Toll Brothers Inc. (TOL), Lennar Corp. (LEN) and KB Home (KBH) all saw pressure amid uncertainty.
Trump's move was highlighted in a social media post emphasizing that "people live in homes, not corporations," which triggered speculation about forced liquidations and broader impacts on Wall Street's real estate strategies. Investors recalibrated risk in the sector quickly, sending stocks lower as they digested the potential implications.
Defense Contractors Hit by Dividend and Buyback Ban
U.S. defense stocks slid sharply midweek after President Trump ordered major defense contractors to stop paying dividends and repurchasing shares until they increase investment in production and maintenance. The move hit income-oriented names particularly hard as investors weighed the implications for capital returns and sector valuations.
The iShares U.S. Aerospace & Defense ETF (ITA) and State Street SPDR Aerospace & Defense ETF (XAR) both fell, while individual contractors including Lockheed Martin Corp. (LMT), Northrop Grumman Corp. (NOC) and Redwire Corp. (RDW) saw notable declines. Trump's comments, aimed at prioritizing defense production over shareholder payouts, underscored broader tensions between government policy and investor expectations in the defense sector.
Aquestive Hit by FDA Setback
Aquestive Therapeutics Inc. (AQST) shares tumbled as the U.S. Food and Drug Administration identified deficiencies in the New Drug Application for its investigational allergy treatment Anaphylm, a sublingual film for severe allergic reactions.
The FDA's findings paused discussions on labeling and post-marketing commitments, sending the stock sharply lower amid concerns over a potential delay ahead of the scheduled January 31, 2026 PDUFA action date. Although the FDA said the review is ongoing and no final decision has been made, the setback triggered heavy selling. Investors are now watching how the company addresses the issues while pursuing global regulatory filings and preparations to respond to the agency's feedback.